A small peptide (XXX) with strong affinity to an anti-TTT receptor therapeutics antibody (blankumab) was investigated to increase the fractional occupation of TTT receptor by blankumab consequently reduce resistance. Previously developed semi-physiological pharmacokinetic models were used to predict antibody and peptide tumor diffusion. Animals chosen were injected with blankumab or blankumab with XXX. ELISA methods were used to quantify concentration of antibody in each sample drawn. Although I was unable to replicate previous results, I was able to understand challenges faced during research and how to investigate solutions through literature.
what do you guys think of this? I've been struggling trying to write these
what do you guys think of this? I've been struggling trying to write these